Skip to main content

Advertisement

Table 1 Summary of the most relevant long-term results in patients with melanoma

From: Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, November 30th 2016

Study mOS (mos) 1-years OS% 2-years OS% 3-years OS% 5-years OS%
CA209-003 [1] 20.3 65 47 41% 35%
CA209-066 [2] NR 70.7 57.7 NA NA
Keynote-001 all pts [3] 24.4 66 50 40% NA
Keynote-001 naïve pts [4] 32.2 73 61 45% NA